Reset filter
Trefwoorden
C13.351.937.418.365 ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

113 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Cycle Dose Drug Form D2R Fallopian Tube Cancer (NCT00108745)

- 09-01-15 - 1 Formulier, 3 Itemgroepen, 41 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values
Cycle Dose Drug Form, GOG-0212, Form D2R Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer NCT00108745 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E74972BD-ECF1-48B2-E034-0003BA3F9857

Cycle Dose Drug Form D2R Fallopian Tube Cancer (NCT00565851)

- 09-01-15 - 1 Formulier, 2 Itemgroepen, 35 Data-elementen, 1 Taal
Itemgroepen: Header, TREATMENT CYCLE AND MODIFICATION
GYNECOLOGIC ONCOLOGY GROUP Cycle Dose Drug Form - FORM D2R Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer NCT00565851 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA671E4E-F217-4DDB-E034-0003BA12F5E7

Cycle Dose Drug Form D2R Fallopian Tube Cancer (NCT00951496)

- 09-01-15 - 1 Formulier, 3 Itemgroepen, 41 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values
Gynecologic Oncology Group Cycle Dose Drug Form (Form D2R) Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT00951496 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4F53E994-CCD2-730F-E044-0003BA3F9857

Fallopian Tube Cancer NCT00262847 Lab - GOG-0218 Specimen Form - 2303734v3.0 - GOG-0218 Specimen Form

- 17-09-21 - 1 Formulier, 7 Itemgroepen, 55 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, SITE CONTACT INFORMATION, GENERAL SPECIMEN INFORMATION, BLOOD/FLUID PRODUCTS, TISSUE/CELLS, GOG TISSUE BANK/LABORATORY INFORMATION, FOOTER MODULE
GOG-0218 Specimen Form Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F0E16A95-3A2C-5BBD-E034-0003BA3F9857

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Survival Information; Form D; Termination Record

- 03-09-19 - 1 Formulier, 9 Itemgroepen, 29 Data-elementen, 1 Taal
Itemgroepen: Survival Information - Month of Report, Survival Information - Review of disease status, Survival Information - Outcome, Form D, Termination Record, Termination Record - Review of Disease Status, Termination Record - Best Overall Response, Termination Record - Study Conclusion, Termination Record - Investigator Signature
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Adverse Events; Serious Adverse Event; Prior and Concomitant Medications

- 03-09-19 - 1 Formulier, 8 Itemgroepen, 61 Data-elementen, 1 Taal
Itemgroepen: Administrative, Are there any non-serious adverse events to report?, Non-Serious adverse Events, Serious Adverse Event #1, Serious Adverse Event #1 - Relevant Laboratory Data, Serious Adverse Event #1 - Signature, Prior and Concomitant Medications, Prior and Concomitant Medications
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- Prior to next Course (Day 25 - 28) - Vital Signs; Tumor Marker (CA-125); Laboratory Tests; Lesion Assessment Record

- 02-09-19 - 1 Formulier, 9 Itemgroepen, 41 Data-elementen, 1 Taal
Itemgroepen: Administrative, Vital Signs, Tumor Marker (CA-125), Laboratory Tests - Haematology, Laboratory Tests - Haematology , Laboratory Tests - Chemistry, Laboratory Tests - Chemistry , Lesion Assessment, Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- (Day 1) - Eligibility; Vital Signs; Administration of Study Medications

- 02-09-19 - 1 Formulier, 6 Itemgroepen, 45 Data-elementen, 1 Taal
Itemgroepen: Administrative, Eligibility, Vital Signs, Administration of Study Medications, Topotecan Administration, Gemcitabine Administration
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- Prior to next Course (Day 25 - 28) - Review of Disease Status; Therapeutic Interventions; End of Course Eligibility; Unscheduled Laboratory Tests; Therapeutic Interventions Log

- 02-09-19 - 1 Formulier, 7 Itemgroepen, 23 Data-elementen, 1 Taal
Itemgroepen: Administrative, Review of Disease Status, Therapeutic Interventions, End of Course Eligibility, Unscheduled Laboratory Tests - Hematology, Unscheduled Laboratory Tests - Hematology, Therapeutic Interventions
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- (Day 8 ) - Vital Signs; Hematology; Administration of Study Medications

- 02-09-19 - 1 Formulier, 7 Itemgroepen, 45 Data-elementen, 1 Taal
Itemgroepen: Administrative, Day 8 Vital Signs, Hematology, Hematology, Day 8 Administration of Study Medications, Topotecan Administration, Gemicitabine Administration
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- (Day 15 ) - Vital Signs; Hematology; Administration of Study Medications

- 02-09-19 - 1 Formulier, 7 Itemgroepen, 45 Data-elementen, 1 Taal
Itemgroepen: Administrative, Day 15 Vital Signs, Hematology, Hematology, Day 15 Administration of Study Medications, Topotecan Administration, Gemcitabine Administration
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 3 Prior to next Course (Day 25 - 28) - Vital Signs; Tumor Marker (CA-125); Laboratory Tests; Lesion Assessment Record

- 01-09-19 - 1 Formulier, 9 Itemgroepen, 40 Data-elementen, 1 Taal
Itemgroepen: Administrative, Vital Signs, Tumor Marker (CA-125), Laboratory Tests - Haematology, Laboratory Tests - Haematology , Laboratory Tests - Chemistry, Laboratory Tests - Chemistry , Lesion Assessment, Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial